• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative

byNeel MistryandTeddy Guo
June 13, 2024
in Chronic Disease, Dermatology, Rheumatology, Surgery
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16.

2. Treatment-related adverse events were infrequent with one fatality across both treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hidradenitis suppurativa (HiS) is a chronic inflammatory disease with limited therapeutic options. Bimekizumab, a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F and IL-17A, has shown potential in treating this condition. This randomized controlled trial aimed to assess the safety and efficacy of bimekizumab in patients with moderate-to-severe HiS. The primary outcome of this study was achieving a HiS clinical response of at least 50% (HiSCR50) at week 16, while the key secondary outcome was the safety profile. According to study results, bimekizumab significantly improved HiSCR50 rates compared to placebo.

Click to read the study in The Lancet

Relevant Reading: Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa

RELATED REPORTS

Atopic dermatitis activity is not associated with cardiovascular risk

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

In-depth [randomized controlled trial]: Between Feb 19, 2020, and Oct 27, 2021, 778 patients were assessed for eligibility across 176 sites in Europe, USA, Canada, Asia, and Australia. Included were patients ≥ 18 years with moderate-to-severe HiS. Altogether, 333 patients (104 in bimekizumab every 2 weeks to week 16 then every 4 weeks to week 48, 98 in bimekizumab every 2 weeks to week 48, 87 in bimekizumab every 4 weeks to week 48, and 44 in placebo to week 16 then bimekizumab every 2 weeks to week 48) were included in the final analysis. The primary outcome of HiSCR50 at week 16 was significantly higher in the bimekizumab groups compared to control (48% vs. 29% in trial I, odds ratio [OR] 2.23, 97.5% confidence interval [CI] 1.16-4.31, p=0.0060 and 52% vs. 32% in trial II, OR 2.29, 97.5% CI 1.22-4.29, p=0.0032). Treatment related adverse events were uncommon (8% in trial I and 5% in trial II) and included hidradenitis, candidiasis, and headache. Only 1 death was reported overall. Findings from this study suggest that bimekizumab is a well-tolerated and effective treatment option for patients with moderate-to-severe hidradenitis suppurativa.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bimekizumabdermatologyHidradenitis suppurativaIL-17IL-17 inhibitorIL-17Askin abscess
Previous Post

Genome sequencing may offer diagnostic utility beyond exome sequencing at acceptable cost

Next Post

Long-term survival improved with use of tebentafusp for metastatic uveal melanoma

RelatedReports

Eczema more prevalent among older adults than previously thought
Cardiology

Atopic dermatitis activity is not associated with cardiovascular risk

April 2, 2026
Medicines in clinical trials collage: a plain white pharmacy bag with a folded top beside capsules and round tablets
All Specialties

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

March 5, 2026
2 Minute Medicine AI Roundup editorial illustration
AI Roundup

2MM: AI Roundup –Lilly launches TuneLab AI drug discovery, smart wound healing bandage, and Punjab cancer screening [September 25th, 2025]

September 28, 2025
Melanoma collage: a magnifying glass over an even mole and an uneven one on skin, with a sun hat and sunglasses
AI Roundup

Artificial intelligence matches dermatologists in melanoma diagnosis

September 15, 2025
Next Post
Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

Long-term survival improved with use of tebentafusp for metastatic uveal melanoma

#VisualAbstract: Low-Dose Daily Aspirin does not Affect the Progression of Age-Related Macular Degeneration

#VisualAbstract: Low-Dose Daily Aspirin does not Affect the Progression of Age-Related Macular Degeneration

Combined immunotherapy may improve survival in metastatic pancreatic cancer

Novo Nordisk: Awiqli is a once-weekly insulin injection for patients with type 2 diabetes

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • CCTA-guided PCI noninferior to IVUS-guided PCI for target-vessel failure
  • Lower resident board pass rates in private-equity backed emergency physician groups
  • Brelovitug met the AZURE-4 primary endpoint in chronic hepatitis delta infection in topline phase 3 results
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.